The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

N.M. Nenasheva

«Russian Medical Academy of Continuous Professional Education

M.Yu. Peredelskaya

Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Healthcare of the Russian Federation;
LLC «Paracelsus Medical Center»

Breathe out!

Authors:

N.M. Nenasheva, M.Yu. Peredelskaya

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2023;(5): 58‑67

Read: 2232 times

Contact the author
Table of contents

To cite this article:

Nenasheva NM, Peredelskaya MYu. Breathe out! Non Nocere. New Therapeutic Journal. 2023;(5):58‑67. (In Russ.)

 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Choice of therapy in a patient with severe uncontrolled asthma.

Authors:

N.M. Nenasheva

«Russian Medical Academy of Continuous Professional Education

M.Yu. Peredelskaya

Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Healthcare of the Russian Federation;
LLC «Paracelsus Medical Center»

Close metadata

References:

  1. Global Initiative for Asthma. 2022 GINA Report. Global Strategy for Asthma Management and Prevention [дата обращения 17 марта 2023]. Available from: GINA Main Report 2022 Front Cover (ginasthma.org).
  2. Dávila González I, Moreno Benítez F, Quirce S. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma. J Investig Allergol Clin Immunol. 2019 Apr;29(2):8 4-93. https://doi.org/10.18176/jiaci.0385
  3. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012 May 4;18(5):71 6-725. https://doi.org/10.1038/nm.2678
  4. Barnes PJ. Pathophysiology of allergic inflammation. Immunol Rev. 2011 Jul;242(1):3 1-50. https://doi.org/10.1111/j.160 0-065X.2011.01020.x
  5. Yu S, Kim HY, Chang YJ, DeKruyff RH, Umetsu DT. Innate lymphoid cells and asthma. J Allergy Clin Immunol. 2014 Apr;133(4):94 3-950; quiz 51. https://doi.org/10.1016/j.jaci.2014.02.015
  6. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015 Jan;16(1):4 5-56. https://doi.org/10.1038/ni.3049
  7. Lloyd CM, Snelgrove RJ. Type 2 immunity: Expanding our view. Sci Immunol. 2018 Jul 6;3(25): eaat1604. https://doi.org/10.1126/sciimmunol.aat1604
  8. Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O’Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Szefler SJ, Sullivan SD, Thomas MD, Wenzel SE, Reddel HK. A new perspective on concepts of asthma severity and control. Eur Respir J. 2008 Sep;32(3):54 5-554. https://doi.org/10.1183/09031936.00155307
  9. Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы, РРО 2021. Бронхиальная астма (2021) (spulmo.ru) [дата обращения 17.02.2023].
  10. GINA DIFFICULT-TO-TREAT & SEVERE ASTHMA in adolescent and adult patients. Diagnosis and Management. A GINA Pocket Guide For Health Professionals. GINA-2022-severe-asthma-slide-set-2.pptx (live.com) [дата обращения 17.02.2023].
  11. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb;43(2):34 3-73. https://doi.org/10.1183/09031936.00202013
  12. Bousquet J, Mantzouranis E, Cruz AA, Aït-Khaled N, Baena-Cagnani CE, Bleecker ER, Brightling CE, Burney P, Bush A, Busse WW, Casale TB, Chan-Yeung M, Chen R, Chowdhury B, Chung KF, Dahl R, Drazen JM, Fabbri LM, Holgate ST, Kauffmann F, Haahtela T, Khaltaev N, Kiley JP, Masjedi MR, Mohammad Y, O’Byrne P, Partridge MR, Rabe KF, Togias A, van Weel C, Wenzel S, Zhong N, Zuberbier T. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010 Nov;126(5):92 6-938. https://doi.org/10.1016/j.jaci.2010.07.019
  13. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D’Agostino R Jr, Castro M, Curran-Everett D, Fitzpatrick AM, Gaston B, Jarjour NN, Sorkness R, Calhoun WJ, Chung KF, Comhair SA, Dweik RA, Israel E, Peters SP, Busse WW, Erzurum SC, Bleecker ER; National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010 Feb 15;181(4):31 5-323. https://doi.org/10.1164/rccm.20090 6-0896OC
  14. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, Wardlaw AJ, Green RH. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008 Aug 1;178(3):21 8-224. https://doi.org/10.1164/rccm.20071 1-1754OC
  15. Siroux V, Basagaña X, Boudier A, Pin I, Garcia-Aymerich J, Vesin A, Slama R, Jarvis D, Anto JM, Kauffmann F, Sunyer J. Identifying adult asthma phenotypes using a clustering approach. Eur Respir J. 2011 Aug;38(2):31 0-317. https://doi.org/10.1183/09031936.00120810
  16. Canonica GW, Colombo GL, Bruno GM, Di Matteo S, Martinotti C, Blasi F, Bucca C, Crimi N, Paggiaro P, Pelaia G, Passalaqua G, Senna G, Heffler E; SANI Network. Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. World Allergy Organ J. 2019 Jan 26;12(1):100007. https://doi.org/10.1016/j.waojou.2018.12.001
  17. Delgado J, Dávila IJ, Domínguez-Ortega J; Severe Asthma Group (SEAIC). Clinical Recommendations for the Management of Biological Treatments in Severe Asthma Patients: A Consensus Statement. J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):3 6-43. https://doi.org/10.18176/jiaci.0638
  18. Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. Thorax. 2002 Jul;57(7):64 3-648. https://doi.org/10.1136/thorax.57.7.643
  19. Gibson PG. Inflammatory phenotypes in adult asthma: clinical applications. Clin Respir J. 2009 Oct;3(4):19 8-206. https://doi.org/10.1111/j.175 2-699X.2009.00162.x
  20. Hudey SN, Ledford DK, Cardet JC. Mechanisms of non-type 2 asthma. Curr Opin Immunol. 2020 Oct;66:12 3-128. https://doi.org/10.1016/j.coi.2020.10.002
  21. Chen M, Shepard K 2nd, Yang M, Raut P, Pazwash H, Holweg CTJ, Choo E. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. Clin Exp Allergy. 2021 Apr;51(4):54 6-555. https://doi.org/10.1111/cea.13790
  22. Dunican EM, Fahy JV. Asthma and corticosteroids: time for a more precise approach to treatment. Eur Respir J. 2017 Jun 29;49(6):1701167. https://doi.org/10.1183/13993003.0116 7-2017
  23. Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall’acqua WW, Stephens GL, Erjefalt JS, Bjermer L, Humbles AA, Gossage D, Wu H, Kiener PA, Spitalny GL, Mackay CR, Molfino NA, Coyle AJ. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010 Jun;125(6):134 4-1353.e2. https://doi.org/10.1016/j.jaci.2010.04.004
  24. Cushen B, Menzies-Gow A. Benralizumab: an updated treatment of eosinophilic asthma. Expert Rev Respir Med. 2020 May;14(5):43 5-444. https://doi.org/10.1080/17476348.2020.1739526
  25. Pelaia C, Calabrese C, Vatrella A, Busceti MT, Garofalo E, Lombardo N, Terracciano R, Pelaia G. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. Biomed Res Int. 2018 May 10;2018:4839230. https://doi.org/10.1155/2018/4839230
  26. Инструкция по применению бенрализумаба. Государственный реестр лекарственных средств (rosminzdrav.ru).
  27. Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir. Med. 2016;111:2 1-29. https://doi.org/10.1016/j.rmed.2016.01.003
  28. Zhu M, Yang J, Chen Y. Efficacy and safety of treatment with benralizumab for eosinophilic asthma. Int Immunopharmacol. 2022 Oct;111:109131. https://doi.org/10.1016/j.intimp.2022.109131
  29. Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, Coyle AJ, Koike M, Spitalny GL, Kiener PA, Geba GP, Molfino NA. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol. 2010 Jun;125(6):123 7-1244.e2. https://doi.org/10.1016/j.jaci.2010.04.005
  30. Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA. J Allergy Clin Immunol. 2013 Nov;132(5):108 6-1096.e5. https://doi.org/10.1016/j.jaci.2013.05.020
  31. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M; CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):212 8-2141. https://doi.org/10.1016/S0140-6736(16)31322-8
  32. Nagase H, Suzukawa M, Oishi K, Matsunaga K. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy. Allergol Int. 2023 Jan;72(1):1 1-23. https://doi.org/10.1016/j.alit.2022.11.008
  33. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M; SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):211 5-2127. https://doi.org/10.1016/S014 0-6736(16)3132 4-1
  34. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M; ZONDA Trial Investigators. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017 Jun 22;376(25):244 8-2458. https://doi.org/10.1056/NEJMoa1703501
  35. Korn S, Bourdin A, Chupp G, Cosio BG, Arbetter D, Shah M, Gil EG. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years. J Allergy Clin Immunol Pract. 2021 Dec;9(12):438 1-4392.e4. https://doi.org/10.1016/j.jaip.2021.07.058
  36. Vitale C, Maglio A, Pelaia C, D’Amato M, Ciampo L, Pelaia G, Molino A, Vatrella A. Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting. J Clin Med. 2023 Jan 27;12(3):985. https://doi.org/10.3390/jcm12030985
  37. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb;43(2):34 3-373. https://doi.org/10.1183/09031936.00202013
  38. Cushen B, Menzies-Gow A. Benralizumab: an updated treatment of eosinophilic asthma. Expert Rev Respir Med. 2020 May;14(5):43 5-444. https://doi.org/10.1080/17476348.2020.1739526
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.